A Comparison of PK and PD Responses Following Single and Repeat Administration of Epinephrine Nasal FMXIN002 4.0 mg and EpiPen 0.3 mg, in Healthy Adults With Allergic Rhinitis
Latest Information Update: 06 Jan 2026
At a glance
- Drugs Epinephrine (Primary) ; Epinephrine (Primary)
- Indications Anaphylaxis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Nasus Pharma
Most Recent Events
- 22 Dec 2025 According to Nasus Pharma media release, the company dosed the first patient in an open-label, fixed-sequence trial designed to evaluate the pharmacokinetic parameters and hemodynamic responses of NS002 compared to EpiPen in up to 50 healthy adults with a history of allergic rhinitis. We expect to report an interim analysis early in the first quarter of 2026.
- 19 Nov 2025 New trial record